TG THERAPEUTICS, INC.

(TGTX)
  Report
Real-time Estimate Cboe BZX  -  05/27 03:40:03 pm EDT
5.175 USD   +2.48%
05/26TG Therapeutics Announces Data Presentations from the ULTIMATE I & II Phase 3 Trials of Ublituximab in Multiple Sclerosis to be Presented at the 2022 Consortium of Multiple Sclerosis Centers Annual Meeting
AQ
05/23TG Therapeutics to Participate in the H.C. Wainwright Global Investment Conference
AQ
05/20Top Midday Decliners
MT
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector news

TG Therapeutics Shares Drop 37% After FDA Imposes Partial Clinical Hold

01/27/2022 | 01:31pm EDT

By Denny Jacob


Shares of TG Therapeutics Inc. fell nearly 37% to $8.75 Thursday after the company disclosed in a regulatory filing that the Food and Drug Administration imposed a partial clinical hold on select studies of one of its treatments.

According to the regulatory filing, Chief Executive Michael Weiss told an investor conference that the partial clinical hold wasn't based on based on any new information the company provided but appeared to be based on the same data and concerns that led to a previously announced Oncologic Drug Advisory Committee meeting, which is set to take place in either March or April. No new patients may be enrolled to the select chronic lymphocytic leukemia and non-Hodgkin's lymphoma studies identified by the FDA as a result of the partial hold, he said.

Trading in TG Therapeutics was paused for volatility at 10:21 a.m. ET and resumed five minutes later.


Write to Denny Jacob at denny.jacob@wsj.com


(END) Dow Jones Newswires

01-27-22 1331ET

All news about TG THERAPEUTICS, INC.
05/26TG Therapeutics Announces Data Presentations from the ULTIMATE I & II Phase 3 Trials of..
AQ
05/23TG Therapeutics to Participate in the H.C. Wainwright Global Investment Conference
AQ
05/20Top Midday Decliners
MT
05/20TG Therapeutics' Shares Plummet After BofA Securities Initiates Coverage at Underperfor..
MT
05/20TG Therapeutics to Participate in the H.C. Wainwright Global Investment Conference
AQ
05/20BofA Securities Starts TG Therapeutics at Underperform With $5 Price Target
MT
05/11TG THERAPEUTICS : Q1 Earnings Snapshot
AQ
05/10TG THERAPEUTICS, INC. MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND ..
AQ
05/10TG Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 20..
CI
04/27TG Therapeutics to Participate in the B. Riley Securities' 2022 Virtual Neuro & Ophthal..
AQ
More news
Analyst Recommendations on TG THERAPEUTICS, INC.
More recommendations
Financials (USD)
Sales 2022 21,6 M - -
Net income 2022 -264 M - -
Net cash 2022 11,7 M - -
P/E ratio 2022 -2,69x
Yield 2022 -
Capitalization 672 M 672 M -
EV / Sales 2022 30,5x
EV / Sales 2023 6,02x
Nbr of Employees 286
Free-Float 91,9%
Chart TG THERAPEUTICS, INC.
Duration : Period :
TG Therapeutics, Inc. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends TG THERAPEUTICS, INC.
Short TermMid-TermLong Term
TrendsBearishBearishBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 9
Last Close Price 5,05 $
Average target price 17,89 $
Spread / Average Target 254%
EPS Revisions
Managers and Directors
Michael Sean Weiss Chairman, President & Chief Executive Officer
Sean A. Power Chief Financial Officer, Secretary & Treasurer
Owen A. O'Connor Chief Scientific Officer
Laurence N. Charney Lead Independent Director
Yann Echelard Independent Director
Sector and Competitors
1st jan.Capi. (M$)
TG THERAPEUTICS, INC.-73.42%672
MODERNA, INC.-46.53%54 016
LONZA GROUP AG-28.07%42 292
IQVIA HOLDINGS INC.-26.37%39 319
SEAGEN INC.-10.44%25 487
ICON PUBLIC LIMITED COMPANY-29.73%17 693